Heard on the Street: The FTC’s effort to block Amgen’s acquisition of Horizon Therapeutics is putting a damper on the recent biotech stocks rally
Federal Trade Commission action to block Amgen-Horizon deal threatens the thesis driving biotech stocks higherThe Federal Trade Commission’s effort to block Amgen’s acquisition of Horizon Therapeutics is putting a damper on the recent biotech stocks rally.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen dealThe deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Read more »
Horizon shares sink on report that FTC will sue to block takeover by AmgenShares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen...
Read more »
FTC to block Amgen's $27.8 billion deal for Horizon Therapeutics - sourceThe U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc's $27.8 billion deal to buy Horizon Therapeutics PLC , a person familiar with the matter told Reuters.
Read more »
FTC Poised to Block Amgen’s $27.8 Billion Deal for Horizon TherapeuticsThe Federal Trade Commission is preparing to block Amgen’s $28 billion deal to buy Horizon Therapeutics
Read more »
FTC sues to block Amgen acquisition of Horizon TherapeuticsThe deal was a bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Read more »
FTC sues to block Amgen’s $26B deal for HorizonRegulators said the deal would give Amgen unfair leverage to block competition for Horizon medications.
Read more »